Latest News

December 2, 2013

ITN Type 1 Diabetes Roundup at the International Diabetes Federation (IDF) and Immunology of Diabetes Society (IDS) Meetings

The International Diabetes Federation (IDF) annual meeting (December 2-6, 2013) and Immunology of Diabetes Society (IDS) annual meeting (December 7-11, 2013) in Australia will feature multiple talks on recent findings from the Immune Tolerance Network's ( ITN’s) portfolio of type 1 diabetes studies. Type 1 diabetes is a challenging disease where so far no therapeutic has been able to reverse or permanently halt the autoimmune attack on pancreatic β-cells.

October 24, 2013

Data from ITN Lupus Nephritis Study to be presented at Upcoming Rheumatology and Nephrology Conferences

Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences.

October 4, 2013

ITN TrialShare Absorbs BioShare

The Immune Tolerance Network (ITN) is retiring ITN BioShare. ITN’s inventory of clinical trial biospecimens is now available through ITN TrialShare. Now that ITN’s biorepository is accessible through TrialShare, all web traffic to BioShare will redirect to www.ITNTrialShare.org.Launched in November of 2010, BioShare was ITN’s initial interface for sharing clinical samples collected from ITN trials with the scientific community.

September 23, 2013

New Publication: Results from the T1DAL Type 1 Diabetes Study

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Dr. Mark Rigby (Indiana University) are published today in The Lancet Diabetes & Endocrinology.Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T lymphocytes, was the first biologic therapy approved for moderate to severe plaque psoriasis. By binding CD2, alefacept inhibits co-stimulation and induces T cell depletion.

September 10, 2013

ITN Mourns the Passing of Lloyd Mayer

It is with great sadness that we report the passing of Lloyd Mayer, MD.

August 28, 2013

New Publication: START Type 1 Diabetes Study Showed No Difference in Insulin Production Decline

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) with the Immune Tolerance Network (ITN), were published in an article today in The Lancet Diabetes & Endocrinology. The study enrolled 58 new-onset type 1 diabetic subjects ages 12-35. The subjects were randomized 2:1 to antithymocyte globulin (ATG) treatment, which is currently licensed for the treatment of organ transplant rejection, or placebo.

August 7, 2013

ITN TrialShare Sees Public Usage Rise Following Publication of the First Manuscript with Embedded Links to the System

In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org). Since then public usage of the system (not including ITN staff and collaborators) has increased dramatically with over 100 new users registering and 3000 total page hits by public users.

August 1, 2013

ITN Achieves Scientific Manuscript First - Provides Open, Interactive Access to Clinical Trial Data with New Publication: Rituximab Therapy Effective for ANCA-associated Vasculitis

In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org). The data published today come from the ITN’s RAVE study led by John Stone, MD (Massachusetts General Hospital) and Ulrich Specks, MD (Mayo Clinic).

July 24, 2013

IMPACT Study Launches Today: Peanut Oral Immunotherapy in Young Children

The Immune Tolerance Network’s (ITN’s) IMPACT Study, “Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children,” opened for enrollment today. This will be the first major study to examine whether oral immunotherapy can lead to durable, lasting tolerance to peanut among young peanut-allergic children. This study will be led by ITN investigator Wesley Burks, MD, Chair of the Department of Pediatrics at UNC Chapel Hill.

July 8, 2013

New Publication: AbATE Type 1 Diabetes Study Reveals Subset of Patients with Strong Response to Therapy

Primary results from the Immune Tolerance Network’s AbATE study (Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes) were published online today in Diabetes. The Phase II AbATE study, led by Kevan Herold, MD (Yale University), tested two doses of anti-CD3 given one year apart in new onset type 1 diabetics compared to control.